Table 4.
Multivariate COX analysis for 3-year OS, 5-year OS, and PFS in ESCC patients
| 5-year OS
|
PFS
|
3-year OS
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 95% CI | HR | P-value | 95% CI | HR | P-value | 95% CI | HR | P-value | |
| TNM staging | 1.04–2.180 | 1.506 | 0.030 | 0.983–2.023 | 1.410 | 0.062 | – | – | – |
| Treatment | 0.593–1.129 | 0.818 | 0.223 | 0.613–1.147 | 0.838 | 0.271 | – | – | – |
| HPV16 | 1.098–3.197 | 1.874 | 0.021 | 1.025–2.954 | 1.740 | 0.040 | 1.255–3.574 | 2.118 | 0.005 |
| p75NTR | 0.441–1.299 | 0.757 | 0.312 | 0.455–1.338 | 0.780 | 0.368 | 0.7388–2.105 | 1.247 | 0.408 |
| PI3K | 1.166–3.299 | 1.961 | 0.011 | 1.240–3.479 | 2.077 | 0.006 | 1.083–3.318 | 1.896 | 0.025 |
Abbreviations: CI, confidence interval; ESCC, esophageal squamous cell carcinoma; HPV16, human papillomavirus 16; HR, hazard ratio; OS, overall survival; PI3K, phosphatidylinositol 3-kinase; p75NTR, low-affinity p75 neurotrophin receptor; PFS, progression-free survival; TNM, tumor node metastasis.